Exelixis, Inc.
Drug-discovery company announces second-quarter 2004 financial results
Published in Pharma Investments, Ventures and Law Weekly, September 19th, 2004
Net loss, under generally accepted accounting principles (GAAP), was approximately $29.3 million, or $0.41 per share, compared to a GAAP net loss of $23.4 million, or $0.39 per share, for the second quarter 2003. Non-GAAP net loss, excluding restructuring expense, acquired in-process research and development, and noncash charges for stock compensation and amortization of intangibles, was approximately $27.0 million, or $0.37 per share, compared to approximately $23.9 million, or $0.40 per share, for the second quarter of 2003.
Cash, cash equivalents, short-term...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- Access Pharmaceuticals, Inc.
Pharmaceutical firm reports loss of $0.17 per share - Akorn, Inc.
Pharmaceutical firm reports 25% increase in revenues - Albany Molecular Research, Inc.
Drug discovery firm reports 22.2% decrease in revenues - Alkermes, Inc.
Pharmaceutical firm reports loss of $0.40 per share - America Oriental Bioengineering
Chinese biotech firm reports 23% revenue increase - Anadys Pharmaceuticals, Inc.
Hepatitis drug maker reports loss of $0.50 per share - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
